A new approach to treating neuroinflammation
NeuroTherapia is a clinical stage company developing new treatments for neuroinflammatory disorders.
Neuroinflammation has now been recognized to play a key role in a range of neurologic disorders such as Alzheimer’s disease (AD), neuropathic pain, multiple sclerosis and ALS. The Company’s lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist with demonstrated CNS activity that targets CB2 receptors on microglia, which significantly reduces the expression of inflammatory agents resulting in neuronal survival and activation.
The pre-clinical efficacy of NTRX-07 has been established in multiple models of Alzheimer’s disease, with a recently completed clinical study demonstrating supportive biological and clinical signals in humans.
Data from our Phase 2a trial of NTRX-07 in Alzheimer’s disease patients continued to demonstrate a favorable safety profile during 28 days of treatment and a pharmacokinetic (PK) profile consistent with preclinical exposure targets, which are expected to drive clinical activity. Exploratory endpoints, including MRI, qEEG, and CSF biomarkers, were directionally supportive of NTRX-07’s neuroinflammatory mechanism of action.